PL3389653T3 - 2-iminobiotyna do zastosowania w leczeniu uszkodzeń komórek mózgowych - Google Patents

2-iminobiotyna do zastosowania w leczeniu uszkodzeń komórek mózgowych

Info

Publication number
PL3389653T3
PL3389653T3 PL16825913.3T PL16825913T PL3389653T3 PL 3389653 T3 PL3389653 T3 PL 3389653T3 PL 16825913 T PL16825913 T PL 16825913T PL 3389653 T3 PL3389653 T3 PL 3389653T3
Authority
PL
Poland
Prior art keywords
iminobiotin
treatment
brain cell
cell injury
injury
Prior art date
Application number
PL16825913.3T
Other languages
English (en)
Inventor
Paul Willem Theresia Josef Leufkens
Cacha Marie Pétronelle Cathérine Dorothée PEETERS
Huibert Alexander TJABBES
Original Assignee
Neurophyxia B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurophyxia B.V. filed Critical Neurophyxia B.V.
Publication of PL3389653T3 publication Critical patent/PL3389653T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL16825913.3T 2015-12-16 2016-12-16 2-iminobiotyna do zastosowania w leczeniu uszkodzeń komórek mózgowych PL3389653T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15200492 2015-12-16
PCT/NL2016/050880 WO2017105237A1 (en) 2015-12-16 2016-12-16 2-iminobiotin for use in the treatment of brain cell injury

Publications (1)

Publication Number Publication Date
PL3389653T3 true PL3389653T3 (pl) 2024-02-26

Family

ID=54936830

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16825913.3T PL3389653T3 (pl) 2015-12-16 2016-12-16 2-iminobiotyna do zastosowania w leczeniu uszkodzeń komórek mózgowych

Country Status (11)

Country Link
US (3) US10525039B2 (pl)
EP (1) EP3389653B1 (pl)
JP (1) JP6975165B2 (pl)
AU (1) AU2016372396B2 (pl)
CA (1) CA3008790A1 (pl)
DK (1) DK3389653T3 (pl)
ES (1) ES2965754T3 (pl)
FI (1) FI3389653T3 (pl)
PL (1) PL3389653T3 (pl)
PT (1) PT3389653T (pl)
WO (1) WO2017105237A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10525039B2 (en) 2015-12-16 2020-01-07 Neurophyxia B.V. 2-iminobiotin for use in the treatment of brain cell injury
US11998001B2 (en) * 2018-02-09 2024-06-04 Yale University Perfusion device for normothermic, ex vivo preservation of a mammalian brain
US20240173301A1 (en) * 2021-03-23 2024-05-30 Neurophyxia B.V. 2-iminobiotin for use in the treatment of stroke
WO2022203505A1 (en) * 2021-03-23 2022-09-29 Neurophyxia B.V. 2-iminobiotin for use in the treatment of stroke

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU772204B2 (en) 1999-01-21 2004-04-22 Bristol-Myers Squibb Company Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method
US7087633B2 (en) 2000-03-31 2006-08-08 Universitair Medisch Centrum Method for treating perinatal asphyxia in a human or animal neonate
WO2001074351A1 (en) 2000-03-31 2001-10-11 Universitair Medisch Centrum Composition for the prevention and/or treatment, in newborn babies, of the effects of complications during childbirth
US7319090B2 (en) 2002-11-27 2008-01-15 University Of North Carolina At Chapel Hill Methods of treating cerebral ischemia
US20090197966A1 (en) 2006-10-04 2009-08-06 Uno Jakob Weber Use of Hypothermia Inducing Drugs
MX338405B (es) 2010-05-26 2016-04-14 Neurophyxia B V Formulaciones de 2-iminobiotina y sus usos.
AU2013264820A1 (en) * 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
GB2504263B (en) 2012-06-08 2015-09-16 Gw Pharma Ltd Synergistic therapies for neuroprotection
US10092591B2 (en) * 2014-02-27 2018-10-09 University Of Alaska Fairbanks Methods and compositions for the treatment of ischemic injury to tissue using therapeutic hypothermia
US10525039B2 (en) 2015-12-16 2020-01-07 Neurophyxia B.V. 2-iminobiotin for use in the treatment of brain cell injury

Also Published As

Publication number Publication date
US10722496B2 (en) 2020-07-28
US11426387B2 (en) 2022-08-30
AU2016372396A1 (en) 2018-06-28
ES2965754T3 (es) 2024-04-16
JP2019501969A (ja) 2019-01-24
FI3389653T3 (fi) 2023-12-18
US20200338046A1 (en) 2020-10-29
US10525039B2 (en) 2020-01-07
WO2017105237A1 (en) 2017-06-22
AU2016372396B2 (en) 2022-04-14
PT3389653T (pt) 2023-12-28
CA3008790A1 (en) 2017-06-22
EP3389653A1 (en) 2018-10-24
JP6975165B2 (ja) 2021-12-01
EP3389653B1 (en) 2023-11-08
US20200147049A1 (en) 2020-05-14
DK3389653T3 (da) 2024-01-02
US20190262316A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
ZA201705673B (en) Methods for treating skin
PT3334422T (pt) Utilização de ácido canabidiólico no tratamento de epilepsia
GB201510664D0 (en) Use of cannabinoids in the treatment of epilepsy
SG10202007559PA (en) Skin treatment apparatus
GB201614522D0 (en) Use of cannabinoids in the treatment of multiple myeloma
AU364343S (en) Skin toning device
GB201403104D0 (en) Skin treatment device
EP3280375C0 (en) BODY MASSAGER
PL3215219T3 (pl) System do zabiegów na skórze
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
SG11201704499WA (en) Agent for hair deforming treatment
PL3215157T3 (pl) Apilimod do stosowania w leczeniu czerniaka
SG11201704497PA (en) Agent for hair deforming treatment
PL3160464T3 (pl) 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
IL276577A (en) Methods for treating cardiac injury
GB201615448D0 (en) Apparatus for dermatological treatment
SG11201704504PA (en) Agent for hair deforming treatment
IL246855A0 (en) Materials for use in the treatment of retinitis
PT3389653T (pt) 2-iminobiotina para utilização no tratamento de lesão celular cerebral
SG11201704493UA (en) Agent for hair deforming treatment
GB2553527B (en) Headgear suitable for use in hydrotherapy
PT3406258T (pt) Medicamento para utilização no tratamento de gota
GB201604658D0 (en) Treatment for pain
PL3291691T3 (pl) Wykorzystanie azotanów w leczeniu poporodowej dysgalakcji u ssaków jednożołądkowych